NCT01112423

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

A Double-Blind, Placebo-Controlled, Parallel-Group, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of BMS-823778 in Non-Diabetic Subjects With Primary Hypercholesterolemia on a Stable Dose of Statin Therapy With or Without Ezetimibe

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	BMS-823778	Capsules, Oral, 2 mg, once daily, 28 days
DRUG	BMS-823778	Capsules, Oral, 10 mg, once daily, 28 days
DRUG	BMS-823778	Capsules, Oral, 20 mg, once daily, 28 days
DRUG	Placebo	Capsules, Oral, 0 mg, once daily, 28 days

Timeline

• Start date: 2010-06-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2010-04-28
• Last updated: 2015-10-12

Locations

12 sites across 3 countries: United States, Australia, Canada